# **RESEARCH ARTICLE**

# **Open Access**



# Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study

A. K. Lofters<sup>1,2,3,4,5\*</sup>, M. L. McBride<sup>6,7</sup>, D. Li<sup>6</sup>, M. Whitehead<sup>8</sup>, R. Moineddin<sup>3,4,5</sup>, L. Jiang<sup>8,9</sup>, E. Grunfeld<sup>3,4,5,10</sup>, P. A. Groome<sup>8,11,12</sup> and for the CanIMPACT Team

# Abstract

**Background:** In Canada, clinical practice guidelines recommend breast cancer screening, but there are gaps in adherence to recommendations for screening, particularly among certain hard-to-reach populations, that may differ by province. We compared stage of diagnosis, proportion of screen-detected breast cancers, and length of diagnostic interval for immigrant women versus long-term residents of BC and Ontario.

**Methods:** We conducted a retrospective cohort study using linked administrative databases in BC and Ontario. We identified all women residing in either province who were diagnosed with incident invasive breast cancer between 2007 and 2011, and determined who was foreign-born using the Immigration Refugee and Citizenship Canada database. We used descriptive statistics and bivariate analyses to describe the sample and study outcomes. We conducted multivariate analyses (modified Poisson regression and quantile regression) to control for potential confounders.

**Results:** There were 14,198 BC women and 46,952 Ontario women included in the study population, of which 11.8 and 11.7% were foreign-born respectively. In both provinces, immigrants and long-term residents had similar primary care access. In both provinces, immigrant women were significantly less likely to have a screen-detected breast cancer (adjusted relative risk 0.88 [0.79–0.96] in BC, 0.88 [0.84–0.93] in Ontario) and had a significantly longer median diagnostic interval (2 [0.2–3.8] days in BC, 5.5 [4.4–6.6] days in Ontario) than long-term residents. Women from East Asia and the Pacific were less likely to have a screen-detected cancer and had a longer diagnostic interval, but were diagnosed at an earlier stage than long-term residents. In Ontario, women from Latin America and the Caribbean and from South Asia were less likely to have a screen-detected cancer, had a longer median diagnostic interval, and were diagnosed at a later stage than long-term residents. These findings were not explained by access to primary care.

**Conclusions:** There are inequalities in breast cancer diagnosis for Canadian immigrant women. We have identified particular immigrant groups (women from Latin America and the Caribbean and from South Asia) that appear to be subject to disparities in the diagnostic process that need to be addressed in order to effectively reduce gaps in care.

Keywords: Immigrant health, Breast cancer, Stage of diagnosis, Health equity, Diagnosis interval, Cancer screening

\* Correspondence: aisha.lofters@utoronto.ca

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

<sup>&</sup>lt;sup>1</sup>Department of Family & Community Medicine, St. Michael's Hospital, 30 Bond St, Toronto M5B 1W8, Canada

 $<sup>^{2}\</sup>mathrm{Centre}$  for Urban Health Solutions, Li Ka Shing Knowledge Institute, Toronto, Canada

# Background

Women in Canada are more likely to develop breast cancer than any other cancer, with 1 in 8 Canadian women expected to develop the disease in their lifetime, and 1 in 31 expected to die from it [1]. Diagnosing cancer at an early stage is one of the most important determinants of a positive outcome, and delays in diagnosis have been associated with disease progression (and thus higher stage at the time of diagnosis) and inefficient healthcare delivery [2–4]. In Canada, clinical practice guidelines recommend mammography for breast cancer screening, but there are province-specific gaps in adherence to recommendations for screening, particularly among certain hard-to-reach populations, and many women are still diagnosed due to symptomatic presentation [5–7].

There are known breast cancer screening inequalities in Canada based on sociodemographic characteristics. In particular, some immigrant women have been found to have lower rates of mammography use than Canadianborn women [6, 9-13]. As well, ethnicity has been associated with stage at breast cancer diagnosis in the province of Ontario, with women of South Asian ethnicity being more likely to be diagnosed at a later stage, and women of Chinese ethnicity being more likely to be diagnosed at an early stage, than the remaining general population [14]. Little is known about the role of sociodemographic characteristics in the length of the diagnostic interval in Canada, although large variation in the length of the diagnostic interval has been observed based on geography [15]. Much remains to be learned about potential disadvantage for immigrants as it relates to a timely breast cancer diagnosis.

As immigrant women from South Asia have been found to have particularly low breast cancer screening rates [6], we hypothesized that women from this region would also have a later stage of diagnosis and a lower proportion of screen-detected breast cancers. We further hypothesized that immigrant class i.e. one's classification upon admission to the country and time in the country would be associated with the diagnostic process based on their association with screening uptake in previous studies [6, 16]. As ethnicity has been linked to the length of the breast cancer diagnostic interval in the literature [17], we also wanted to explore the relationship of the aforementioned immigrant-related variables with the length of the diagnostic interval. Comparing populationlevel results on cancer care across provincial/territorial healthcare delivery systems would identify important similarities and differences between jurisdictions, and contextual differences that might affect the gaps in care [8]. The identification of immigrant factors that are related to lower screening rates and longer diagnostic intervals could help guide outreach efforts to improve access.

Together, the provinces of British Columbia (BC) and Ontario receive more than half of all immigrants to Canada [18]. Both provinces have organized breast screening programs that recommend biennial screening with mammography for average-risk women aged 50– 74 years [5, 7]. In this study, we aimed to compare: i) stage of diagnosis, ii) the proportion of screen-detected breast cancers, and iii) the length of the diagnostic interval for immigrant women versus long-term residents of BC and Ontario. We explored differences within immigrants by characterizing them in three ways: by region of origin, immigrant class, and time in Canada.

# Methods

## Study design

This study was conducted as part of the Canadian Team to Improve Community-Based Cancer Care along the Continuum (CanIMPACT), a multi-province multi-method program of research aimed at improving integration and coordination of care along the cancer care continuum [19]. We conducted a retrospective cohort study using linked administrative databases in two of the CanIMPACT participating provinces: Ontario and BC.

# Data sources

Data sources for both provinces included the provincial cancer registries, health insurance plan patient registry data, physician billing claims data, and the federal government's Immigration Refugee and Citizenship Canada (IRCC) database. We used the provincial cancer registries (BC Cancer Registry and Ontario Cancer Registry) to identify the study cohort and to determine date of cancer diagnosis, detection method and cancer stage [20]. Patient registry data (BC Medical Services Plan Client Registry and Ontario Registered Persons Database) were used to obtain age, sex and postal code. Billing claims data (BC Medical Services Plan Claims Database and Ontario Health Insurance Plan data) captured outpatient physician services covered under the two provinces' universal health insurance plans [21, 22]. The IRCC database was used to identify Canadian immigrants who arrived from 1985 onward, and includes detailed demographic information such as country of birth, immigrant class, and date of achieving permanent residency status for those who could be either deterministically or probabilistically linked to existing databases [23]. Immigrant class refers to the IRCC classification of immigrants upon admission to the country, specifically: economic (those selected on the basis of their ability to become economically established in Canada), family (those sponsored by a family member), and refugee (those fleeing their countries because of fear of persecution). These provincial populationlevel administrative databases were linked using unique encoded identifiers and analysed at the ICES in

Ontario and Population Data in BC. The study was approved by the Health Sciences and Affiliated Hospitals Research Ethics Board at Queen's University in Ontario, and the BC Cancer Agency and University of British Columbia Research Ethics Board in British Columbia. Data access approvals were obtained from all data stewards in each province. Patient consent was deemed as not required because the research involved no more than minimal risk, the research did not involve an intervention, lack of consent was unlikely to adversely affect patient welfare, and it was impracticable to obtain consent. Due to data access and use constraints which do not readily permit data to leave the respective provinces [24], the analysis was conducted separately in each province.

# Study population

We identified all women residing in Ontario or BC who were diagnosed with incident invasive breast cancer between January 1, 2007 and December 31, 2011. Women were excluded if they did not have a valid health card number or were living outside of the province at the time of diagnosis. Both provinces have universal health insurance whereby all permanent residents are eligible for a health card i.e. for medically necessary health care [25]. Women were also excluded if they had a history of in situ breast cancer, any non-melanoma cancer, or non-solid breast tumour.

The IRCC database was used to identify women who were immigrants to Canada since 1985, and to determine their country of birth, immigrant class, and permanent landing date. Countries of birth were then classified into world regions based on a modified version of the World Bank classification system [6, 26–30]. Women who were not in the IRCC database were classified as "long-term residents", as some of these women would be Canadian-born and some would be earlier immigrants who had arrived prior to 1985. Women's immigrant class was categorized as economic, family, refugee or other, depending on their reason for immigration to Canada. Landing date was used to classify women as having been in Canada for less than 10 years or for 10 years or more.

# Study outcomes

We considered three outcomes: cancer stage at diagnosis (I-IV) [31, 32], whether the breast cancer was screendetected or not, and the length of the diagnostic interval. The diagnostic interval was defined as the time from the date of the first cancer-related physician encounter, diagnostic investigation or screening date to the date of breast cancer diagnosis.

# Study variables

We retrieved data on specific possible modifiers of risk, prioritized in the CanIMPACT program, namely comorbidities, income and age at diagnosis. These factors have been associated with breast cancer screening uptake in Canada [6, 16, 33]. Co-morbidities were defined using Aggregated Diagnosis Groups (ADGs) from the Johns Hopkins Adjusted Clinical Groups (ACG) Case Mix System, which identifies morbidities from diagnosis codes in outpatient billing and inpatient (hospital) records [34]. The ADGs represent groups of conditions with similar healthcare experience relating to attributes such as severity and duration of disease; multimorbidity was defined as the number of ADGs per individual at diagnosis. Neighbourhood income quintile was defined based on a woman's residential postal code at the time of diagnosis, whereby Canadian 2006 Census household income data was used to create community-specific income quintiles [35]. Age at diagnosis was obtained from the aforementioned provincial registries.

As breast cancer screening is often recommended and/or ordered by a primary care physician, and as primary care physicians often play a key role in breast cancer diagnosis, we considered primary care access to be on the causal pathway. We did not include primary care access as a confounder, but we did collect primary care data. Continuity of primary care was defined based on the baseline Usual Provider of Care (UPC) index i.e. the proportion of all primary care visits during the 6 to 30 months before diagnosis that were made to the primary care provider most frequently visited (among those women with at least 3 primary care visits in that time period). We also quantified the number of visits to a primary care provider during the 6 months before diagnosis.

#### Analyses

We used descriptive statistics and bivariate analyses to describe the sample and the study outcomes. We also conducted multivariate analyses to control for potential confounders. Modified Poisson regression was used to estimate relative risk for stage of diagnosis, which was dichotomized to stage I-II versus stage III-IV, and for cancers that were screen-detected versus not. We dichotomized stage in this manner as 5-year relative survival drops from 93 to 72% for stage II versus stage III [36]. Quantile regression was used to explore differences in the median of the diagnostic interval. Variables included in multivariate analyses were age at diagnosis, multimorbidity, neighbourhood income quintile, and immigrant status. Quantile regression analyses also included stage at diagnosis, as the diagnostic interval tends to be shorter for later stage disease.

To explore which immigrant characteristics were associated with our outcomes, all models were repeated, with immigrant women stratified by each of: region of origin, immigrant class and time in Canada. These variables were not put into one model due to concerns about multicollinearity and interpretation of adjusted results. To justify this stratified approach, post hoc, multivariable regression models were conducted in both provinces to assess for the presence of interaction between region of origin, immigrant class, and time in Canada.

# Results

There were 14,198 BC women and 46,952 Ontario women included in the study population. Immigrants made up 11.8 and 11.7% of the provincial cohorts respectively (Table 1). East Asia and the Pacific was the most common source region for immigrants in both provinces, representing 6.7 and 3.5% of the respective cohorts. The economic class was the most common immigration class in both provinces, but the proportion of refugees in Ontario was approximately twice that of BC. The majority of immigrants had been in Canada for at least 10 years.

Characteristics of women with breast cancer varied between the two provinces and between regions of origin (Table 2, Table 3). In both provinces, immigrant women had a similar mean number of primary care visits in the

**Table 1** Immigration-related characteristics of the study population in BC and Ontario

		BC	Ontario
	N (%)	14,198 (100)	46,952 (100)
	Long-term residents	12,520 (88.2)	41,457 (88.3)
	Immigrants	1678 (11.8)	5495 (11.7)
Region	East Asia & Pacific	948 (6.7)	1636 (3.5)
	Eastern Europe & Central Asia	121 (0.9)	933 (2.0)
	Latin American & Caribbean	64 (0.5)	752 (1.6)
	Middle East & North Africa	93 (0.7)	513 (1.1)
	South Asia	191 (1.4)	968 (2.1)
	Sub-Saharan Africa	56 (0.4)	261 (0.6)
	USA/New Zealand/ Australia	68 (0.5)	121 (0.3)
	Western Europe	137 (1.0)	311 (0.7)
Immigrant Class	Economic	961 (6.8)	2496 (5.3)
	Family	609 (4.3)	2190 (4.7)
	Refugee	94 (0.7)	699 (1.5)
	Other	14 (0.1)	110 (0.2)
Years since	< 10 years	613 (4.3)	1981 (4.2)
immigration	> = 10 years	1065 (7.5)	3514 (7.5)

six months prior to diagnosis versus long-term residents (3.3 + 2.9 for long-term residents vs. 2.9 + 2.4 for immigrants in BC, mean 3.4 + 3.3 for long-term residents vs. 4.0 + 3.2 for immigrants in Ontario), but were less likely to have a high UPC index. In both provinces, immigrant women were younger at diagnosis. In BC, women from Eastern Europe and Central Asia (29.8%) and from South Asia (27.8%) were most represented in the lowest income quintile, as compared to Ontario where women from Latin America and the Caribbean (30.9%) and from Sub-Saharan Africa (34.9%) were most represented in the lowest income quintile. Ontario immigrants generally had more co-morbidities than those in BC, and screen-detected breast cancers were less prevalent in Ontario than in BC. In both provinces, immigrant women had fewer screen-detected breast cancers and a lower prevalence of a Stage I diagnosis than long-term residents. South Asian women in both provinces had a particularly low prevalence of Stage I diagnosis (26.7% for BC, 25.8% for Ontario). Ontario women from Latin America and the Caribbean had the lowest probability of being screen-detected overall (17.4%).

In multivariate analysis, immigrant women as a group were not significantly different than long-term residents for stage I/II vs. stage III/IV of diagnosis in either province (Table 4). However, women from East Asia and the Pacific were significantly more likely to be diagnosed at stage I/II than long-term residents in both provinces (adjusted relative risk with 95% confidence interval: 1.28 [1.08–1.52] in BC, 1.05 [1.03–1.08] in Ontario). In Ontario, women were significantly less likely to be diagnosed at stage I/II if they were from Eastern Europe and Central Asia, Latin America and the Caribbean, or South Asia. Although not statistically significant, the BC point estimates for these same groups were in the same direction as the Ontario results. In BC, women from the economic immigrant class were significantly more likely to be diagnosed at stage I/II (adjusted relative risk or ARR with 95% confidence interval or CI: 1.20 [1.02-1.42]), while women from the family class trended toward a lesser likelihood of stage I/II diagnosis. Time in Canada was not significantly associated with stage of diagnosis in either province.

Immigrant women overall were significantly less likely to have a screen-detected breast cancer in both provinces (ARR with 95% CI: 0.88 [0.79–0.96] in BC, 0.88 [0.84–0.93] in Ontario) and women from East Asia and the Pacific were significantly less likely to have a screen-detected cancer in both provinces (Table 5). In Ontario, women were significantly less likely to have a screen-detected cancer if they were from Latin America and the Caribbean (ARR with 95% CI: 0.80 [0.69–0.94]) or from South Asia (ARR with 95% CI: 0.80 [0.71–0.91]). In BC, although marginally significant, the point estimate

I able Z Characteristics	of the study pop	Ulation in BC,	stratified by I	mmigrant st	atus and regior	n of origin					
Variable	Value	Long-term residents	lmmigrants	East Asia & Pacific	Eastern Europe & Central Asia	Latin America & Caribbean	Middle East & North Africa	South Asia	Sub-Saharan Africa	USA/New Zealand/Australia	Western Europe
N (%)		12,520 (88.2)	1678 (11.8)	948 (6.7)	121 (0.8)	64 (0.5)	93 (0.7)	191 (1.4)	56 (0.4)	68 (0.5)	137 (1.0)
Primary care access variab	les										
Baseline UPC	0 visits	933 (7.5)	207 (12.3)	117 (12.3)	17 (14.1)	S=5	16-20	12 (6.3)	6-10	6-10	19 (13.9)
index score	1-2 visits	1694 (13.5)	(0) 0	153 (16.1)	17 (14.1)	S=>	<=5	19 (10.0)	<=5	<=5	24 (17.5)
	UPC < =.75 (low)	4641(37.1)	591 (35.2)	322 (34.0)	42 (34.7)	25 (39.06)	36 (38.7)	69 (36.1)	19 (33.9)	24 (35.3)	54 (39.4)
	UPC > 0.75 (high)	5252 (42.0)	638 (38.0)	356 (37.6)	45 (37.2)	28 (43.75)	29 (31.2)	91 (47.6)	21 (37.5)	28 (41.2)	40 (29.2)
Primary care visits in 6	Mean±SD	3.3 ± 2.9	2.9±2.4	2.8±2.4	2.9 ± 2.4	2.6 ± 2.0	2.7 ± 2.4	2.8 ± 2.9	2.5 ± 1.9	3.0±2.7	2.7 ± 2.4
mths prior to diagnosis	Median (IQR)	3 (1–4)	2 (1-4)	2 (1–4)	2 (1–4)	3 (1–4)	2 (0–5)	3 (2–5)	2 (1–4)	3 (1–4)	2 (1–4)
Control variables											
Age at diagnosis	Mean ± SD	63.1 ± 13.6	53.4 ± 12.3	52.6±11.8	54.6 ± 12.1	51. 8 ± 12.0	52.6 ± 10.9	54.6 ± 13.1	52.7±13.0	52.1 ± 11.2	53.7 ± 13.3
Co-morbidities (ADGs)	0 5	6916 (55.2)	1092 (65.1)	649 (68.5)	74 (61.2)	39 (60.9)	58 (62.4)	101 (52.9)	36 (64.3)	38 (55.9)	97 (70.8)
	6 9	4154 (33.2)	468 (27.9)	253 (26.7)	37 (30.6)	21-25	23 (24.7)	65 (34.0)	16-20	21–25	26 (19.0)
	+ 01	1450 (11.6)	118 (7.0)	46 (4.9)	10 (8.3)	<=-5	12 (12.9)	25 (13.1)	<=5	<=5	14 (10.2)
Income quintile	1 (lowest)	2247 (18.0)	399 (23.8)	245 (25.8)	36 (29.8)	16 (25)	14 (15.1)	53 (27.8)	6-10	14 (20.6)	11-15
	2	2413 (19.3)	389 (23.2)	218 (23.0)	23 (19.0)	11 (17.2)	18 (19.4)	74 (38.7)	6-10	6-10	30 (21.9)
	S	2400 (19.2)	336 (20.0)	189 (19.9)	23 (19.0)	12 (18.8)	18 (19.4)	34 (17.8)	17 (30.4)	14 (20.6)	29 (21.2)
	4	2518 (20.1)	247 (14.7)	139 (14.7)	16 (13.2)	6-10	18 (19.4)	20 (10.5)	6-10	13 (19.1)	23 (16.8)
	5	2707 (21.6)	257 (15.3)	130 (13.7)	17 (14.1)	11-15	18 (19.4)	6-10	16 (28.6)	16 (23.5)	41 (29.9)
	Missing	235 (1.9)	50 (3.0)	27 (2.9)	6 (5.0)	<=-5	7 (7.53)	<=5	(0) 0	<=5	<=5
Outcome variabels											
Stage at diagnosis	_	5297 (42.3)	669 (39.9)	396 (41.8)	45 (37.2)	29 (45.3)	36 (38.7)	51 (26.7)	26 (46.4)	26 (38.2)	60 (43.8)
	=	3974 (31.7)	576 (34.3)	329 (34.7)	43 (35.5)	19 (29.7)	25 (26.9)	85 (44.5)	15 (26.8)	23 (33.8)	37 (27.0)
	≡	1549 (12.4)	254 (15.1)	123 (13.0)	23 (19.0)	12 (18.8)	19 (20.4)	38 (19.9)	8 (14.3)	9 (13.2)	22 (16.1)
	≥	542 (4.3)	55 (3.3)	21 (2.2)	<=5	<u>S</u> =>	<=5	7 (3.66)	6-10	<=2	7 (5.1)
	Unknown	1158 (9.3)	124 (7.4)	79 (8.3)	<=5	S=5	6-10	10 (5.24)	<=5	6-10	11 (8.03)
Screen-detected	n (%) screen- detected	4470 (35.7)	477 (28.4)	259 (27.3)	33 (27.3)	27 (42.2)	27 (42.2)	61 (31.9)	16 (28.6)	16 (23.5)	35 (25.6)
Diagnostic Interval	Median (IQR)	32 (17–55)	30 (18–50)	31 (18–50)	41 (30–55)	20 (14–45)	26 (17–44)	31 (16–47)	38 (19–66)	29 (20–51)	28 (19–57)
(screened patients)	90th percentile	81	84	85	87	70	76	73	98	80	80
Diagnostic Interval	Median (IQR)	30 (14–63)	34 (15–72)	35 (16–75)	23 (11–57)	38 (17–93)	34 (15–73)	41 (21–74)	23 (11–63)	29 (13–65)	22 (11–69)
(Symptom-atic patients)	90th percentile	120	141	143	126	173	148	120	187	144	117
P-value <.001 for all variable	s for comparison of in	mmigrants versus	long-term resid	ents							

New         caldersi         Pack         Canad Automatic         Caldebase         Num         Automatic         Second Automatic         Caldebase         Second Automatic         Second Automatic<		Value	Long-term	Immigrants	East Asia &	Eastern Europe &	Latin American &	Middle East &	South Asia	Sub-Saharan	USA/New	Western
N (6)         N (6) <thn (6)<="" th="">         N (6)         <th< th=""><th></th><th></th><th>residents</th><th></th><th>Pacific</th><th>Central Asia</th><th>Caribbean</th><th>North Africa</th><th></th><th>Africa</th><th>Zealand/Australia</th><th>Europe</th></th<></thn>			residents		Pacific	Central Asia	Caribbean	North Africa		Africa	Zealand/Australia	Europe
	N (%)		41,456 (88.3)	5495 (11.7)	1636 (3.5)	933 (2.0)	752 (1.6)	513 (1.1)	968 (2.1)	261 (0.6)	121 (0.3)	311 (0.7)
	Primary care access variable:	10										
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Baseline UPC index score	0 visits	3022 (7.3)	565 (10.3)	136 (8.3)	103 (11.0)	62 (8.2)	91 (17.7)	91 (9.4)	25 (9.6)	19 (15.7)	38 (12.2)
UCC <=/30001         UCC <=/30011         UCC          UCC <=/30011         UCC		1–2 visits	4496 (10.8)	509 (9.3)	156 (9.5)	115 (12.3)	65 (8.6)	33 (6.4)	62 (6.4)	17 (6.5)	18 (14.9)	43 (13.8)
Unc. 0.75/high         2.323 (6.0)         2.324 (6.1)         3.54 (5.1)         3.14 (5.1)         3		UPC < =.75(low)	10,703 (25.8)	1796 (32.7)	507 (31.0)	289 (31.0)	270 (35.9)	160 (31.2)	333 (34.4)	109 (41.8)	38 (31.4)	90 (28.9)
Prowy are wells         Mean ± D		UPC > 0.75(high)	23,235 (56.0)	2625 (47.8)	837 (51.2)	426 (45.7)	355 (47.2)	229 (44.6)	482 (49.8)	110 (42.1)	46 (38.0)	140 (45.0)
6 mths plation diagonals         Mean (Qa)         3 (1-a)         3 (2-a)         3 (2-a)         3 (2-a)         2 (1-a)         3 (1-a)         3 (1-a)           Control valiables         Actan (Qa)         3 (1-a)         <	Primary care visits in	Mean±SD	3.4 ± 3.3	4.0±3.2	4.0 ± 3.0	3.5 ± 3.1	4.2 ± 3.2	4.2 ± 3.5	4.5 ± 3.4	3.9±3.5	3.1 ± 3.7	3.2 ± 3.0
Control valiables         Amenta SD         619.113         53.4.112         54.4.113         53.4.112         54.4.113         53.4.112         54.4.113         53.4.133         53.4.133         53.7.130 <td>6 mths prior to diagnosis</td> <td>Median (IQR)</td> <td>3 (1–4)</td> <td>3 (2–5)</td> <td>3 (2–5)</td> <td>3 (2–5)</td> <td>3 (2–5)</td> <td>3 (2–6)</td> <td>4 (2–6)</td> <td>3 (2–5)</td> <td>2 (1–4)</td> <td>3 (1–4)</td>	6 mths prior to diagnosis	Median (IQR)	3 (1–4)	3 (2–5)	3 (2–5)	3 (2–5)	3 (2–5)	3 (2–6)	4 (2–6)	3 (2–5)	2 (1–4)	3 (1–4)
Age at diagnosis         (ise in the formation of the forma	Control variables											
Comobicities (AGGs)         0 - 5         2,321 (49.0)         2,465 (50.2)         8,25 (51.1)         3,40 (45.2)         2,52 (49.1)         1,75 (4.1)         3,55 (56.4)         3,7 (30)         6,67 (73)           10 +         (19.4)         (11.1) <td>Age at diagnosis</td> <td>Mean±SD</td> <td>61.9±13.6</td> <td>53.2 ± 12.6</td> <td>51.8±11.2</td> <td>54.3 ± 13.1</td> <td>53.1 ± 13.0</td> <td>53.4 ± 12.2</td> <td>54.6 ± 13.1</td> <td>52.7 ± 13.0</td> <td>52.1 ± 11.2</td> <td>53.7 ± 13.3</td>	Age at diagnosis	Mean±SD	61.9±13.6	53.2 ± 12.6	51.8±11.2	54.3 ± 13.1	53.1 ± 13.0	53.4 ± 12.2	54.6 ± 13.1	52.7 ± 13.0	52.1 ± 11.2	53.7 ± 13.3
	Co-morbidities (ADGs)	0 5	20,321 (49.0)	2760 (50.2)	823 (50.3)	495 (53.1)	340 (45.2)	252 (49.1)	471 (48.7)	132 (50.6)	69 (57.0)	111 (35.7)
(0+         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (13)         (14)         (12)         (14)         (14)         (12)         (12)         (14)         (12)         (14)         (12)         (12)         (12)         (12)         (12)		6 9	14,942 (36.0)	1994 (36.3)	617 (37.7)	320 (34.3)	309 (41.1)	175 (34.1)	355 (36.7)	95 (36.4)	37 (30.6)	86 (27.7)
Income quintie         1 (bowet)         6720 (16.)         14 (12.5)         16 (712)         22 (30.9)         12 (4.2.2)         24 (4.2.1)         21 (4.9.1)         71 (4.0)         59 (19.0)           2         737 (19.1)         117 (21.3)         387 (23.7)         167 (17.9)         206 (27.4)         81 (55)         24 (4.2.1)         20 (6.5)         64 (4.8)           3         8006 (19.3)         109 (20.0)         330 (20.2)         160 (17.1)         147 (19.5)         175 (18.9)         21 (6.1)         20 (6.5)         64 (13.6)           4         9017 (13.0)         132 (18.0)         21 (6.1)         147 (19.5)         177 (18.9)         21 (6.1)         21 (6.1)         21 (6.1)         21 (6.1)         21 (6.1)         21 (6.1)         21 (6.1)         21 (2.3) <td></td> <td>10 +</td> <td>6193 (14.9)</td> <td>741 (13.5)</td> <td>196 (12.0)</td> <td>118 (12.6)</td> <td>103 (13.7)</td> <td>86 (16.8)</td> <td>142 (14.7)</td> <td>34 (13.0)</td> <td>15 (12.4)</td> <td>47 (15.1)</td>		10 +	6193 (14.9)	741 (13.5)	196 (12.0)	118 (12.6)	103 (13.7)	86 (16.8)	142 (14.7)	34 (13.0)	15 (12.4)	47 (15.1)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Income quintile	1 (lowest)	6720 (16.2)	1411 (25.7)	414 (25.3)	210 (22.5)	232 (30.9)	124 (24.2)	264 (27.3)	91 (34.9)	17 (14.0)	59 (19.0)
3         8006 (193)         1097 (20)         330 (202)         160 (171)         147 (195)         102 (199)         25 (211)         20 (165)         46 (145)           4         9017 (218)         1032 (183)         287 (175)         176 -180         177 (121)         177 (122)         177 (122)           Mising         150 (0.4)         <=5		2	7917 (19.1)	1173 (21.3)	387 (23.7)	167 (17.9)	206 (27.4)	81 (15.8)	214 (22.1)	39 (14.9)	15 (12.4)	64 (20.6)
		c	8006 (19.3)	1099 (20.0)	330 (20.2)	160 (17.1)	147 (19.5)	102 (19.9)	239 (24.7)	55 (21.1)	20 (16.5)	46 (14.8)
5         946 (233)         776-780         211-215         176-180         67 (89)         94 (183)         76 (79)         34 (130)         42 (34.7)         71 (228)           Missing         150 (0.4)         <=5		4	9017 (21.8)	1032 (18.8)	287 (17.5)	218 (23.4)	100 (13.3)	112 (21.8)	175 (18.1)	42 (16.1)	27 (22.3)	71 (22.8)
Misring         150 (0.4)         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <=5         <		5	9646 (23.3)	776-780	211-215	176–180	67 (8.9)	94 (18.3)	76 (7.9)	34 (13.0)	42 (34.7)	71 (22.8)
Outcome variables         I         15,732 (37)         1736 (316)         586 (35.8)         294 (31.5)         197 (36.2)         164 (32.0)         257 (32.2)         52 (43.0)         109 (35.0)           I         1         15,732 (37.9)         1736 (31.6)         586 (35.8)         234 (31.5)         197 (36.2)         164 (32.0)         257 (32.2)         52 (43.0)         109 (35.0)           I         1         44624 (35.3)         193 (36.1)         602 (36.8)         338 (36.2)         288 (38.3)         197 (38.4)         31 (37.4)         107 (34.4)           II         5271 (127)         837 (15.2)         196 (12.0)         176 (18.9)         131 (17.4)         131 (17.4)         131 (17.4)         131 (17.4)         131 (17.4)         141 (16.6)         38 (14.6)         147 (14.1)           N         1849 (45.7)         196 (12.0)         33 (12.5)         43 (41.1)         73 (14.2)         141 (16.6)         38 (14.6)         107 (34.4)           N         N         1849 (45.7)         196 (12.0)         131 (17.4)         131 (17.4)         131 (17.4)         131 (17.4)         131 (17.6)         38 (14.6)         140 (14.1)           N         N         1849 (45.7)         131 (17.4)         131 (17.4)         131 (17.4)         101 (25.0)<		Missing	150 (0.4)	<=5	<=5	<=5	0 (0.0)	0 (0:0)	0 (0.0)	0 (0:0)	0 (0:0)	0 (0:0)
Stage at diagnosis         I         15,732 (37.9)         1736 (31.6)         586 (35.8)         294 (31.5)         197 (36.2)         164 (32.0)         250 (25.8)         84 (32.2)         52 (43.0)         109 (35.0)           I         14,624 (35.3)         1983 (36.1)         62 (36.8)         38 (36.2)         288 (38.3)         197 (38.4)         321 (33.2)         55 (36.4)         35 (28.9)         107 (34.4)           II         5271 (12.7)         837 (15.2)         196 (12.0)         176 (18.9)         131 (17.4)         73 (14.2)         161 (16.6)         38 (14.6)         14 (4.1)           W         1849 (45.)         210 (3.8)         43 (2.6)         38 (4.1)         43 (5.7)         13 (2.7)         13 (2.5)         42 (4.3)         13 (13.4)         44 (4.1)           Unknown         3980 (9.6)         729 (13.3)         209 (12.8)         87 (9.3)         93 (12.4)         66 (12.9)         194 (20.0)         51 (19.9)         107 (34.9)           Unknown         3980 (9.6)         729 (13.3)         209 (12.8)         87 (9.3)         93 (12.4)         66 (12.9)         194 (20.0)         51 (19.9)         10 (13.1)           Screen detected         1(9.6)         131 (17.4)         121 (23.6)         132 (13.9)         12 (13.4)         66 (12.9)<	Outcome variables											
II         14,624 (35.3)         1983 (36.1)         602 (36.8)         338 (36.2)         288 (38.3)         197 (38.4)         37 (33.2)         5 (36.4)         35 (28.9)         107 (34.4)           III         5271 (127)         837 (15.2)         196 (12.0)         176 (18.9)         131 (17.4)         73 (14.2)         161 (16.6)         38 (14.6)         8 (14.1)         44 (14.1)           N         1849 (45)         210 (33.8)         43 (2.5)         38 (4.1)         43 (5.7)         13 (2.5)         42 (4.3)         18 (14.9)         44 (14.1)           Nr         1849 (45)         210 (33.8)         43 (2.5)         38 (4.1)         43 (5.7)         13 (2.5)         42 (4.3)         13 (13.9)         64 (13.9)         44 (14.1)           Nr         1849 (45)         210 (33.1)         209 (12.3)         38 (4.1)         43 (5.7)         13 (2.5)         42 (4.3)         13 (13.9)         65 (12.9)         12 (12	Stage at diagnosis	_	15,732 (37.9)	1736 (31.6)	586 (35.8)	294 (31.5)	197 (26.2)	164 (32.0)	250 (25.8)	84 (32.2)	52 (43.0)	109 (35.0)
III $5271(127)$ $837(15.2)$ $196(120)$ $176(189)$ $131(174)$ $73(142)$ $161(166)$ $38(14.6)$ $18(14.9)$ $44(14.1)$ N $1849(45)$ $210(38)$ $43(2.6)$ $38(4.1)$ $43(5.7)$ $13(2.5)$ $42(4.3)$ $13(50)$ $6(50)$ $12(3.9)$ Unknown $3980(96)$ $729(13.3)$ $209(12.8)$ $87(9.3)$ $93(12.4)$ $66(129)$ $194(200)$ $31(11.9)$ $10(83)$ $39(12.5)$ Screen detected $n(\%)$ screen- $11,876(28.6)$ $1081(197)$ $295(18.0)$ $191(205)$ $131(17.4)$ $121(23.6)$ $194(200)$ $52(19.9)$ $28(23.1)$ $69(222)$ Diagnostic IntervalMedian (IOR) $28(15-47)$ $33(19-55)$ $38(19-76)$ $31(17-49)$ $33(19-50)$ $33(19-50)$ $28(13-48)$ $69(12-73)$ Diagnostic IntervalMedian (IOR) $28(15-74)$ $38(19-76)$ $31(17-49)$ $32(1-58)$ $32(1-58)$ $32(1-58)$ $28(13-48)$ Diagnostic IntervalMedian (IOR) $28(15-74)$ $38(19-76)$ $31(17-49)$ $32(19-50)$ $32(19-50)$ $22(9-35)$ $28(13-48)$ Diagnostic IntervalMedian (IOR) $38(19-76)$ $38(19-76)$ $38(19-76)$ $32(19-79)$ $32(19-70)$ $32(19-70)$ $32(16-78)$ $28(15-77)$ Diagnostic IntervalMedian (IOR) $38(19-76)$ $38(19-76)$ $38(19-76)$ $32(19-76)$ $32(19-76)$ $32(19-76)$ $32(19-76)$ $32(19-76)$ Diagnostic IntervalMedian (IOR) $38(19-76)$ $38(19-76)$ $38(19-77)$ <td< td=""><td></td><td>=</td><td>14,624 (35.3)</td><td>1983 (36.1)</td><td>602 (36.8)</td><td>338 (36.2)</td><td>288 (38.3)</td><td>197 (38.4)</td><td>321 (33.2)</td><td>95 (36.4)</td><td>35 (28.9)</td><td>107 (34.4)</td></td<>		=	14,624 (35.3)	1983 (36.1)	602 (36.8)	338 (36.2)	288 (38.3)	197 (38.4)	321 (33.2)	95 (36.4)	35 (28.9)	107 (34.4)
IV         1849 (45)         210 (38)         43 (2.6)         38 (4.1)         43 (5.7)         13 (2.5)         42 (4.3)         13 (5.0)         6 (5.0)         12 (3.9)           Unknown         3980 (96)         729 (13.3)         209 (12.8)         87 (9.3)         93 (12.4)         66 (12.9)         194 (200)         31 (11.9)         10 (8.3)         39 (12.5)           Screen detected         n (%) screen-         11,876 (28.6)         1081 (19.7)         295 (18.0)         191 (20.5)         131 (17.4)         121 (23.6)         194 (20.0)         52 (19.9)         28 (23.1)         69 (22.2)           Diagnostic Interval         Median (QR)         28 (15-47)         33 (19-56)         38 (13-74)         33 (21-58)         30 (20-57)         33 (19-50)         53 (13-48)         69 (12.4)         69 (12.9)         28 (13-48)         69 (23.1)		≡	5271 (12.7)	837 (15.2)	196 (12.0)	176 (18.9)	131 (17.4)	73 (14.2)	161 (16.6)	38 (14.6)	18 (14.9)	44 (14.1)
Unknown         3980 (9.6)         729 (13.3)         209 (12.8)         87 (9.3)         93 (12.4)         66 (12.9)         194 (20.0)         31 (11.9)         10 (8.3)         39 (12.5)           Screen detected         n (%) screen-         11,876 (28.6)         1081 (19.7)         295 (18.0)         191 (20.5)         131 (17.4)         121 (23.6)         194 (20.0)         52 (19.9)         28 (23.1)         69 (22.2)           Diagnostic Interval         Median (QR)         28 (15-47)         33 (19-55)         38 (23-60)         31 (17.49)         121 (23.6)         194 (20.0)         52 (19.9)         28 (23.1)         69 (22.2)           Diagnostic Interval         Median (QR)         28 (15-47)         33 (17-49)         33 (21-58)         30 (20-57)         33 (21-49)         28 (13-48)         69 (13-48)           Cscreened patients)         90th percentile         73         86         91         76         74         76         107           Diagnostic Interval         Median (QR)         33 (19-56)         38 (19-76)         41 (21-78)         32 (15-73)         35 (17-64)         76         97 (15-73)         36 (15-77)           Diagnostic Interval         Median (QR)         33 (19-56)         38 (19-76)         31 (10-77)         32 (15-68)         36 (15-77)		≥	1849 (4.5)	210 (3.8)	43 (2.6)	38 (4.1)	43 (5.7)	13 (2.5)	42 (4.3)	13 (5.0)	6 (5.0)	12 (3.9)
Screen detected         n (%) screen-         11,876 (28,6)         1081 (19.7)         295 (18.0)         191 (20.5)         131 (17.4)         121 (23.6)         194 (20.0)         52 (19.9)         28 (23.1)         69 (22.2)           Diagnostic Interval         Median (IQR)         28 (15-47)         33 (19-56)         31 (17-49)         33 (21-58)         30 (20-57)         33 (19-50)         32 (13-49)         28 (13-48)           Diagnostic Interval         Median (IQR)         28 (15-47)         33 (19-56)         38 (19-76)         31 (17-49)         33 (21-58)         30 (20-57)         33 (19-50)         21 (3-48)         28 (13-48)           Oth percentile         73         86         91         76         99         107         84         74         76         107           Diagnostic Interval         Median (IQR)         33 (19-76)         38 (19-76)         41 (21-78)         32 (15-73)         35 (17-64)         40 (19-77)         36 (15-77)           Using to static patients         Median (IQR)         38 (19-76)         38 (19-76)         31 (10-77)         32 (15-73)         35 (17-64)         40 (19-77)         36 (15-77)         36 (15-77)         36 (15-77)         36 (15-77)         36 (15-77)         36 (15-77)         36 (15-77)         37 (15-68)         36 (15-77) <td></td> <td>Unknown</td> <td>3980 (9.6)</td> <td>729 (13.3)</td> <td>209 (12.8)</td> <td>87 (9.3)</td> <td>93 (12:4)</td> <td>66 (12.9)</td> <td>194 (20.0)</td> <td>31 (11.9)</td> <td>10 (8.3)</td> <td>39 (12.5)</td>		Unknown	3980 (9.6)	729 (13.3)	209 (12.8)	87 (9.3)	93 (12:4)	66 (12.9)	194 (20.0)	31 (11.9)	10 (8.3)	39 (12.5)
Diagnostic Interval         Median (IQR)         28 (15-47)         33 (19-55)         38 (23-60)         31 (17-49)         33 (21-58)         30 (20-57)         33 (19-50)         23 (13-48)         28 (13-48)           (Screened patients)         90th percentile         73         86         91         76         99         107         84         74         76         107           Diagnostic Interval         Median (IQR)         33 (15-66)         38 (19-76)         44 (22-82)         35 (16-73)         41 (21-78)         32 (15-73)         32 (15-77)         32 (15-77)         32 (16-77)         36 (15-77)           Diagnostic Interval         Median (IQR)         33 (15-66)         38 (19-76)         44 (22-82)         35 (16-73)         32 (15-73)         35 (17-64)         40 (19-77)         36 (15-77)           (Symptomatic patients)         90th percentile         120         130         120         110         112         142         133 (15-77)	Screen detected	n (%) screen- detected	11,876 (28.6)	1081 (19.7)	295 (18.0)	191 (20.5)	131 (17.4)	121 (23.6)	194 (20.0)	52 (19.9)	28 (23.1)	69 (22.2)
(Screened patients)         90th percentile         73         86         91         76         107           Diagnostic Interval         Median (IQR)         33 (15–66)         38 (19–76)         44 (22–82)         35 (16–73)         41 (21–78)         32 (15–73)         35 (17–64)         40 (19–77)         32 (15–77)           Symptomatic patients)         90th percentile         126         130         136         127         140         120         112         142         133	Diagnostic Interval	Median (IQR)	28 (15–47)	33 (19–55)	38 (23–60)	31 (17–49)	33 (21–58)	30 (20–57)	33 (19–50)	33 (21–49)	22 (9–35)	28 (13–48)
Diagnostic Interval         Median (IQR)         33 (15-66)         38 (19-76)         44 (22-82)         35 (16-73)         41 (21-73)         35 (17-64)         40 (19-77)         32 (15-73)         36 (15-77)           (Symptomatic patients)         90th percentile         126         130         136         127         140         120         118         112         142         133	(Screened patients)	90th percentile	73	86	91	76	66	107	84	74	76	107
(Symptomatic patients) 90th percentile 126 130 136 127 140 120 118 112 142 133	Diagnostic Interval	Median (IQR)	33 (15–66)	38 (19–76)	44 (22–82)	35 (16–73)	41 (21–78)	32 (15–73)	35 (17–64)	40 (19–77)	32 (16–68)	36 (15–77)
	(Symptomatic patients)	90th percentile	126	130	136	127	140	120	118	112	142	133

Lofters et al. BMC Cancer (2019) 19:42

**Table 4** Adjusted relative risk (ARR) of stage I/II vs. stage III/IV (reference) stage at diagnosis<sup>a</sup>

	BC	Ontario
Immigrants overall	ARR [95% CI]	ARR [95% CI]
Long-term residents	0.96 [0.85–1.09]	0.98 [0.97-1.00]
Region of Origin	1.0	1.0
East Asia & Pacific	1.28 [1.08–1.52]	1.05 [1.03–1.08]
Eastern Europe & Central Asia	0.86 [0.59–1.26]	0.94 [0.91–0.98]
Latin America & Caribbean	0.98 [0.57–1.70]	0.93 [0.89–0.97]
Middle East & North Africa	0.72 [0.48–1.09]	1.01 [0.97–1.06]
South Asia	0.79 [0.58–1.06]	0.93 [0.89–0.97]
Sub-Saharan Africa	0.80 [0.47–1.36]	0.99 [0.92–1.05]
USA/New Zealand/Australia	0.91 [0.53–1.57]	0.98 [0.89–1.09]
Western Europe	0.86 [0.60-1.24]	1.01 [0.95–1.07]
Long-term residents	1.0	1.0
Immigrant Class	ARR [95% CI]	ARR [95% CI]
Economic	1.20 [1.02–1.42]	1.00 [0.98–1.03]
Family	0.87 [0.73–1.04]	0.97 [0.95–1.00]
Refugee	0.98 [0.62–1.54]	0.96 [0.92–1.00]
Other	0.68 [0.28–1.65]	1.00 [0.91–1.11]
Long-term residents	1.0	1.0
Time in Canada	ARR [95% CI]	ARR [95% CI]
Less than 10 years	0.98 [0.81–1.17]	0.99 [0.96–1.02]
10 years or more	1.08 [0.92–1.26]	0.98 [0.96–1.00]
Long-term residents	1.0	1.0

<sup>a</sup>Separate analyses were run stratifying immigrant women by 1) region of origin, 2) immigrant class and 3) time in Canada. Control variables in all models were age at diagnosis, level of co-morbidity and neighbourhood income guintile. Significant results are bolded

was in the opposite direction from Ontario for Latin American/Caribbean women. In both provinces, arriving via family class and being in Canada for less than 10 years were significantly associated with a lower likelihood of screen-detected cancer, with those in Canada 10 years or more in Ontario also having fewer screen-detected cancers.

In quantile regression analyses, the adjusted median diagnostic interval was 2 days longer in BC and 5.5 days longer in Ontario for immigrant women overall (Table 6). The adjusted difference in the diagnostic interval was consistently longer in Ontario than in BC across groups. Women from East Asia and the Pacific and from South Asia had significantly longer diagnostic intervals at the median in both provinces, reaching 9.5 days for East Asian women in Ontario. Ontario women from Latin America and the Caribbean also waited 9 days longer than long-term residents. In BC, only women in the family class had a statistically significantly longer wait than long-term residents at 4 days, while in Ontario, all three class groups had the same result as the immigrant group as a whole.

Table	5 Adjusted	relative	risk (ARR)	of having	a scree	n-detected
breast	cancer <sup>a</sup>					

	BC	Ontario
Immigrants overall	ARR [95% CI]	ARR [95% CI]
Long-term residents	0.88 [0.79–0.96]	0.88 [0.84–0.93]
Region of Origin	1.0	1.0
East Asia & Pacific	0.85 [0.75–0.97]	0.86 [0.78–0.95]
Eastern Europe & Central Asia	0.86 [0.61-1.22]	0.89 [0.79–1.01]
Latin America & Caribbean	1.34 [0.92–1.96]	0.80 [0.69–0.94]
Middle East & North Africa	0.96 [0.67–1.38]	1.00 [0.86–1.16]
South Asia	0.96 [0.74–1.23]	0.80 [0.71–0.91]
Sub-Saharan Africa	0.88 [0.54–1.43]	0.94 [0.75–1.18]
USA/New Zealand/ Australia	0.67 [0.41-1.10]	1.00 [0.74–1.35]
Western Europe	0.77 [0.55–1.08]	1.09 [0.90–1.32]
Long-term residents	1.0	1.0
Immigrant Class	ARR [95% CI]	ARR [95% CI]
Economic	0.91 [0.80–1.03]	0.93 [0.86-1.00]
Family	0.81 [0.69–0.95]	0.83 [0.76–0.90]
Refugee	0.95 [0.66–1.36]	0.88 [0.76–1.01]
Other	1.09 [0.41-2.92]	0.94 [0.66–1.33]
Long-term residents	1.0	1.0
Time in Canada	ARR [95% CI]	ARR [95% CI]
Less than 10 years	0.80 [0.68–0.95]	0.76 [0.69–0.85]
10 years or more	0.91 [0.81-1.02]	0.94 [0.88–0.99]
Long-term residents	1.0	1.0

<sup>a</sup>Separate analyses were run stratifying immigrant women by 1) region of origin, 2) immigrant class and 3) time in Canada. Control variables in the models were age at diagnosis, level of co-morbidity and neighbourhood income guintile. Significant results are bolded

In post hoc analyses, for both provinces, the interaction between years since immigration and immigrant class was statistically significant (p < 0.0001) for screening, which justified our analytic approach.

# Discussion

In this population-based retrospective cohort study in two Canadian provinces with large foreign-born populations, we have shown that there are inequalities in breast cancer diagnosis for immigrant women. In both provinces, immigrant women overall were significantly less likely to have a screen-detected breast cancer and had a significantly longer median diagnostic interval than long-term residents after adjusting for important control variables. However, we found significant subgroup variation when we characterized immigrant status in different ways. In both provinces, women from East Asia and the Pacific, the largest immigrant group, were less likely to have a screen-detected cancer and had a longer diagnostic interval (after adjusting for stage of diagnosis), but were diagnosed at an earlier stage than long-term

<b>Table 6</b> Adjusted difference in length of diagnostic interval
measured in days at the 50th percentile, where the outcome
was the length of the diagnostic interval. Long-term residents
served as the reference group for each analysis <sup>a</sup>

	BC	Ontario
	Median [with 95% confidence intervals]	Median [with 95% confidence intervals]
Immigrants overall	2 [0.2–3.8]	5.5 [4.4–6.6]
Region of origin		
East Asia & Pacific	2 [0.1–3.9]	9.5 [7.1–11.9]
Eastern Europe & Central Asia	0.4 [-5.5-6.3]	4.5 [2.0–7.0]
Latin America & Caribbean	2.2 [-6.9-11.2]	9.0 [5.7–12.3]
Middle East & North Africa	-2 [-10.9-6.9]	1.8 [-2.4-6.0]
South Asia	6.7 [2.0–11.3]	3.5 [1.1–5.9]
Sub-Saharan Africa	1.0[-14.6-16.6]	5.5 [- 1.6-12.6]
USA/New Zealand/ Australia	-0.3[- 12.2-11.5]	-2.5 [-7.2-2.2]
Western Europe	- 5[- 10.8-0.8]	1.2 [-4.5-6.9]
Immigrant class		
Economic	1[- 1.3-3.3]	5.5 [3.8–7.2]
Family	4 [0.6–7.4]	5.5 [3.9–7.1]
Refugee	0.2[-9.2-9.6]	5.5 [2.1–8.9]
Other	-9.5[-48.3-29.3]	7 [-0.4-14.4]
Time in Canada		
Less than 10 years	1.4[-1.7-4.4]	5.5 [3.6–7.4]
10 years or more	2[-0.3-4.3]	5.5 [4.1–6.9]

<sup>a</sup>Separate analyses were run stratifying immigrant women by 1) region of origin, 2) immigrant class and 3) time in Canada. Control variables in the models were age at diagnosis, stage at diagnosis, level of co-morbidity and neighbourhood income quintile. Significant results are bolded

residents. In Ontario, both women from Latin America and the Caribbean and women from South Asia were less likely to have a screen-detected cancer, had a longer median diagnostic interval after adjusting for stage, and were diagnosed at a later stage than long-term residents. Immigrant class and time in Canada were also associated with breast cancer diagnosis, with women in the family class being at higher risk of having breast cancers that were not screen-detected, of having longer median diagnostic intervals, and of being diagnosed at a later stage. In both provinces, women in Canada for less than 10 years were less likely to have a screen-detected cancer with evidence of a dose response for time in Canada. The differences we found do not seem to be explained by lack of primary care access, as immigrant women and long-term residents made a similar number of primary care visits during the six months prior to diagnosis. However, it is noteworthy that immigrant women had a lower prevalence of a high UPC index.

Our findings that immigrant women from certain world regions were less likely to have a screen-detected breast cancer are consistent with existing literature whereby some immigrant women in Canada have been found to have lower uptake of screening mammography [6, 9–13]. Vahabi et al.'s Ontario study found South Asian women, the most recent immigrant women, and women in the family and refugee classes to be particularly at risk of under-screening [6], in line with our findings. Surprisingly, in that same study, women from Latin America and the Caribbean had higher screening rates than long-term residents [6], yet, we found them to be less likely to have a screen-detected breast cancer. The reasons for this cannot be determined from the current study but are not out of line with US literature. African-American women have both similar screening rates and a higher incidence of aggressive breast cancers compared to White American women [37-41], and most African-American women and many Caribbean and Latin American women in Ontario would be of West African ancestry. These findings taken together may reflect that women of West African ancestry are genetically more susceptible to aggressive breast cancers that are more likely to be detected by symptoms than by screening [42].

We found that women from Latin America and the Caribbean and women from South Asia tended to be diagnosed with breast cancer at a later stage, which is consistent both with our findings that they were less likely to have a screen-detected cancer and with other literature [42, 43]. However, it is surprising that East Asian women were diagnosed at an earlier stage than long-term residents, despite being *less* likely to have a screen-detected cancer. Other studies have found East Asian women to be more likely to be diagnosed at an earlier stage than other ethnocultural groups [14, 42, 43] and to have tumours that are less likely to have spread at the time of diagnosis [43, 44]. More research is needed to explore the causes for these findings, but it is important to note that variation also exists within immigrant groups; for example, Filipino women may be at increased risk of more aggressive breast cancers when compared to other East Asian women [45]. Of note, although we did not find a difference in diagnosis of stage I-II vs. III-IV for immigrant women overall, Iqbal et al. found that immigrant women overall in Ontario were significantly less likely than Canadian-born women to be diagnosed with stage I (vs. II-IV) breast cancer [43].

It is concerning that the length of the diagnostic interval was significantly longer for some immigrant women even after adjustment for stage of diagnosis and considering no differences in primary care access, and longer in Ontario than in BC. In previous literature, Black and South Asian ethnicity have been associated with a longer diagnostic interval for breast cancer in the UK, as has Hispanic and African-American ethnicity in the US, with inequitable access to appropriate, timely and highquality care being suggested as possible causes [17, 46–49]. Although it is admittedly unlikely that a delay in the order of days would contribute to significantly worse survival, more timely diagnosis processes for patients may reduce psychological stress experienced during this period of uncertainty [50–52].

Our study is the first Canadian population-based study that we know of to use data from two provinces to explore breast cancer diagnosis for immigrant women from all major regions of the world. Using data from two provinces allowed us to highlight similar findings of immigration-related disparities in two distinct health care systems, and to highlight important differences worth exploring such as a longer adjusted difference in the length of the diagnostic interval for immigrant women in Ontario versus BC. Lipscomb et al. have noted the importance from a policy perspective of comparative analyses across health systems in cancer care [8]. We were also able to make use of an established and rich database capturing immigrants who came to Canada as long as 26 years before the study period. This rich data source allowed us to characterize the immigrant populations in different ways that will be useful for targeted screening and diagnostic service policies and program planning. However, there are several limitations. First, the IRCC database is not complete. It does not include immigrants who arrived before 1985, therefore we designated our reference group as long-term residents. It also does not include immigrants who landed in other provinces and then moved to BC or Ontario. An estimated 9.6% of immigrants residing in Ontario and 20.2% of immigrants residing in BC first landed in another province [53]. These immigrant women would have been included as long-term residents. The differences we found may have been larger if we had been able to accurately classify these interprovincial migrants. Second, the sample size was small for some immigrant subgroups in BC, and thus some of our analyses in this province were under-powered. Third, stage of diagnosis was not available for all study participants. However, there is no reason to believe that this information would be missing in a biased manner. Fourth, we did not take into account the variation that exists within immigrant groups. Woods et al. found that breast cancer screening participation rates in BC were 37.9% for women from Eastern Europe and Central Asia, but within that group, rates from individual countries ranged from 35.0 to 49.0% [29]. Collapsing birth countries into regions may also explain some of the interprovincial differences we observed. For example, according to the 2016 Canada Census, the most common Latin American and Caribbean

source country for BC is Mexico, whereas for Ontario, the most common source country within that region is Jamaica. Differences for this world region in the two provinces may be partly explained by this different country mix. Fifth, it is not possible to determine the reasons for the differences we observed using available administrative data. Systemic barriers, discrimination, cultural barriers, and genetic susceptibility due to shared ancestry are all potential reasons, and it is possible that all play some role. Finally, we did not explore the impact of the differences we found in the diagnostic process on breast cancer-specific survival, which would be crucial to explore in future studies. The disparities we found in screendetected cancers were notably larger than the disparities we found in stage of diagnosis, bringing to mind questions that have previously been raised in the literature about the role of screening mammography in breast cancer survival and in over-diagnosis [54-57].

We have shown that there are inequalities in breast cancer diagnosis for some immigrant women in the Canadian provinces of BC and Ontario. In particular, we have highlighted particular immigrant groups that appear to have unique issues that need to be explored in order to effectively reduce these gaps in care. Future research exploring these findings must particularly consider how the quality of primary care can be improved for these women, and must explore if immigrant women experience disparities in breast cancer-specific survival.

#### Abbreviations

ACG: Adjusted Clinical Groups; ADG: Aggregated Diagnosis Groups; ARR: Adjusted Relative Risk; BC: British Columbia; CanIMPACT: Canadian Team to Improve Community-Based Cancer Care along the Continuum; Cl: Confidence Interval; IRCC: Immigration Refugee and Citizenship Canada; UPC: Usual Provider of Care

#### Acknowledgements

This study was supported by the ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by the ICES or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. Parts of this material are based on data and information provided by Cancer Care Ontario (CCO). The opinions, results, views, and conclusions reported in this paper are those of the authors and do not necessarily reflect those of CCO. No endorsement by CCO is intended or should be inferred. The BC Cancer Agency and BC Ministry of Health approved access to and use of the data for this study, facilitated by Population Data BC. All inferences, opinions, and conclusions drawn in this paper are those of the authors, and do not reflect the opinions or policies of the data stewards. Immigration data was obtained from the Immigration, Refugees and Citizenship Canada database held at the ICES. AL is supported by a New Investigator Award from the Canadian Institutes of Health Research and as a Clinician Scientist by the University of Toronto Department of Family & Community Medicine. In addition to the authors, the membership of the CanIMPACT Administrative Health Data Group who undertook this work include: Natalie Biswanger, CancerCare Manitoba, Winnipeg, Manitoba; Kathleen Decker, Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba; Cynthia Kendell, Cancer Outcomes Research Program, Dalhousie University and Nova Scotia Health Authority, Halifax, Nova Scotia; Monika Krzyzanowska, University Health Network, Toronto, Ontario, Canada; Sharon Matthias, CanIMPACT Patient Advisory Committee, Alberta; Nicole Mittmann, Cancer

Care Ontario, Toronto, Ontario; Geoff Porter, Dalhousie University, Halifax, Nova Scotia; Dawn Powell, CanlMPACT Patient Advisory Committee, Ontario; Donna Turner, CancerCare Manitoba, Winnipeg, Manitoba; Robin Urquhart, Dalhousie University, Halifax, Nova Scotia; Bonnie Vick, CanlMPACT Patient Advisory Committee, Saskatchewan; Marcy Winget, Stanford University School of Medicine, Stanford, California, USA; Yan Yuan, University of Alberta, Edmonton, Alberta.

#### Funding

This study was funded by the Canadian Institutes of Health Research (CIHR) (grant 128272). Additional funding received by The Canadian Centre for Applied Research in Cancer Control (ARCC), funded by the Canadian Cancer Society grant #2015-703549. The funding body played no role in the design of the study, the collection, analysis and interpretation of data, or in writing the manuscript.

# Availability of data and materials

The data supporting the conclusions of this article are not available in a public repository, in accordance with institutional policies. They are housed at the ICES and Population Data BC.

#### Authors' contributions

AL took primary responsibility for the design of the study, the interpretation of data, and drafting and revising the article. She gave final approval of the version to be published. MM provided advice and direction for the study design and contributed to data interpretation. She revised the article critically for important intellectual content and gave final approval of the version to be published. DL provided advice and direction for the study design and contributed to data analysis and interpretation. She revised the article critically for important intellectual content and gave final approval of the version to be published. MW provided advice and direction for the study design and contributed to data analysis and interpretation. She revised the article critically for important intellectual content and gave final approval of the version to be published. RM provided advice and direction for the study design and contributed to data interpretation. He revised the article critically for important intellectual content and gave final approval of the version to be published. LJ provided advice and direction for the study design and contributed to data interpretation. She revised the article critically for important intellectual content and gave final approval of the version to be published. EG provided advice and direction for the study design, and data acquisition, analysis and interpretation. She revised the article critically for important intellectual content and gave final approval of the version to be published. PG provided advice and direction for the study design, and data acquisition, analysis and interpretation. She revised the article critically for important intellectual content and gave final approval of the version to be published.

#### Ethics approval and consent to participate

The study was approved by the Health Sciences and Affiliated Hospitals Research Ethics Board at Queen's University in Ontario, and the BC Cancer Agency and University of British Columbia Research Ethics Board in British Columbia.

#### Consent for publication

n/a

# Competing interests

The authors declare that they have no competing interests.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# Author details

<sup>1</sup>Department of Family & Community Medicine, St. Michael's Hospital, 30 Bond St, Toronto M5B 1W8, Canada. <sup>2</sup>Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Toronto, Canada. <sup>3</sup>Department of Family & Community Medicine, University of Toronto, Toronto, Canada. <sup>4</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. <sup>5</sup>ICES, Toronto, Canada. <sup>6</sup>BC Cancer, Vancouver, Canada. <sup>7</sup>School of Population and Public Health, University of British Columbia, Vancouver, Canada. <sup>8</sup>ICES, Queen's University, Kingston, Canada. <sup>9</sup>Critical Care Services Ontario, Toronto, Ontario, Canada. <sup>10</sup>Ontario Institute for Cancer Research, Toronto, ON,

## Received: 2 March 2018 Accepted: 9 December 2018 Published online: 09 January 2019

#### References

- 1. Canadian Cancer Statistics 2017. Toronto; 2017.
- Prognostic factors in cancer. 3rd ed. New Jersey: J. Wiley and Sons; 2006.
   Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer. Br J Surg.
- 2004;91(1):49–53.
   Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, et al. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012;136(3):813–21.
- Ontario Breast Screening Program: 20th anniversary report 1990–2010. Toronto; 2010.
- Vahabi M, Lofters A, Kumar M, Glazier RH. Breast cancer screening disparities among immigrant women by world region of origin: a population-based study in Ontario, Canada. Cancer Med. 2016;5(7):1670–86. https://doi.org/10.1002/cam4.700.
- BC Cancer Screening: BC Cancer; 2018. Available from: http://www.bccancer. bc.ca/screening/health-professionals/breast [24 Jul 2018]
- Lipscomb J, Yabroff KR, Hornbrook MC, Gigli A, Francisci S, Krahn M, et al. Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr. 2013;2013(46):124–30.
- Sun Z, Xiong H, Kearney A, Zhang J, Liu W, Huang G, et al. Breast cancer screening among Asian immigrant women in Canada. Cancer Epidemiol. 2010;34(1):73–8.
- 10. Shields M, Wilkins K. An update on mammography use in Canada. Health Rep. 2009;20(3):7–19.
- Maxwell CJ, Bancej CM, Snider J. Predictors of mammography use among Canadian women aged 50-69: findings from the 1996/97 National Population Health Survey. CMAJ. 2001;164(3):329–34.
- 12. Vahabi M. Knowledge of breast cancer and screening practices among Iranian immigrant women in Toronto. J Community Health. 2011;36(2):265–73.
- Glazier RH, Creatore MI, Gozdyra P, Matheson FI, Steele LS, Boyle E, et al. Geographic methods for understanding and responding to disparities in mammography use in Toronto, Canada. J Gen Intern Med. 2004;19(9):952–61.
- Ginsburg OM, Fischer HD, Shah BR, Lipscombe L, Fu L, Anderson GM, et al. A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario. Curr Oncol. 2015;22(2):97–104.
- Yuan Y, Li M, Yang J, Elliot T, Dabbs K, Dickinson JA, et al. Factors related to breast cancer detection mode and time to diagnosis in Alberta, Canada: a population-based retrospective cohort study. BMC Health Serv Res. 2016;16:65.
- Vahabi M, Lofters A, Kumar M, Glazier RH. Breast cancer screening disparities among urban immigrants: a population-based study in Ontario. Canada BMC Public Health. 2015;15:679.
- 17. Martins T, Hamilton W, Ukoumunne OC. Ethnic inequalities in time to diagnosis of cancer: a systematic review. BMC Fam Pract. 2013;14:197.
- Ethnic Diversity and Immigration Ottawa: Statistics Canada; 2016 [Available from: http://www.statcan.gcca/pub/11-402-x/2012000/chap/imm/imm-eng.htm.
- 19. CanIMPACT: Improving Cancer Care Together Toronto [Available from: http://www.canimpact.utoronto.ca.
- 20. BC Cancer Agency Registry Data, V2, Population Data BC: BC Cancer Agency; 2011 [Available from: http://www.popdata.bc.ca/data.
- Medical Services Plan (MSP) Payment Information File. V2, MOH (2011): British Columbia Ministry of Health; 2011 [Available from: http://www. popdata.bc.ca/data.
- Consolidation File (MSP Registration & Premium Billing). V2, Population Data BC: British Columbia Ministry of Health (2011); 2011 [Available from: http://www.popdata.bc.ca/data.
- Chiu M, Lebenbaum M, Lam K, Chong N, Azimaee M, Iron K, et al. Describing the linkages of the immigration, refugees and citizenship Canada permanent resident data and vital statistics death registry to Ontario's administrative health database. BMC Med Inform Decis Mak. 2016;16(1):135.
- Groome PA, McBride ML, Jiang L, Kendell C, Decker KM, Grunfeld E, et al. Lessons learned: it takes a village to understand inter-sectoral care using administrative data across jurisdictions. Int J Pop Data Sci. 2018. https://doi. org/10.23889/ijpds.v3i3.440.
- Madore O. The Canada health act: overview and options. Ottawa: Economics Division, Parliamentary Research Branch, Library of Parliament; 2004.

- Lofters AK, Hwang SW, Moineddin R, Glazier RH. Cervical cancer screening among urban immigrants by region of origin: a population-based cohort study. Prev Med. 2010;51(6):509–16.
- Lofters AK, Ng R, Lobb R. Primary care physician characteristics associated with cancer screening: a retrospective cohort study in Ontario, Canada. Cancer Med. 2015;4(2):212–23. https://doi.org/10.1002/cam4.358.
- Shen SC, Lofters A, Tinmouth J, Paszat L, Rabeneck L, Glazier RH. Predictors of non-adherence to colorectal cancer screening among immigrants to Ontario, Canada: a population-based study. Prev Med. 2018;111:180–9.
- Woods RR, McGrail KM, Kliewer EV, Kazanjian A, Mar C, Kan L, et al. Breast screening participation and retention among immigrants and nonimmigrants in British Columbia: a population-based study. Cancer Med. 2018;7(8):4044–67. https://doi.org/10.1002/cam4.1608.
- Creatore MI, Moineddin R, Booth G, Manuel DH, DesMeules M, McDermott S, et al. Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario. Canada CMAJ. 2010;182(8):781–9.
- 31. AJCC Cancer staging manual. New York: Springer; 2009.
- The TNM Classification of Malignant Tumours. Hoboken, NJ: Wiley-Blackwell; 2009.
- Guilcher SJ, Lofters A, Glazier RH, Jaglal SB, Voth J, Bayoumi AM. Level of disability, multi-morbidity and breast cancer screening: does severity matter? Prev Med. 2014;67:193–8.
- Johns Hopkins ACG System: the Johns Hopkins University. Available from: https://www.hopkinsacg.org [21 Sept 2017]
- Wilkins R, Peters PA. Automated geographic coding based on the Statistics Canada postal code conversion files including postal codes through May 2011. Ottawa: Statistics Canada; 2012.
- Survival statistics for breast cancer: Canadian Cancer Society; 2018 [Available from: http://www.cancer.ca/en/cancer-information/cancer-type/breast/ prognosis-and-survival/survival-statistics/?region=gc.
- Morris GJ, Mitchell EP. Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc. 2008;100(6):698–702.
- Newman LA. Breast Cancer disparities: socioeconomic factors versus biology. Ann Surg Oncol. 2017;24(10):2869–75. https://doi.org/10.1245/ s10434-017-5977-1.
- Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL. Triplenegative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15(4):248–54.
- Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, et al. Comparison of the genomic landscape between primary breast Cancer in African American versus white women and the Association of Racial Differences with Tumor Recurrence. J Clin Oncol. 2015;33(31):3621–7.
- Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015;149(1):31–9.
- Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.
- Iqbal J, Ginsburg O, Fischer HD, Austin PC, Creatore MI, Narod SA, et al. A Population-Based Cross-Sectional Study Comparing Breast Cancer Stage at Diagnosis between Immigrant and Canadian-Born Women in Ontario. Breast J. 2017;23(5):525–36. https://doi.org/10.1111/tbj.12785.
- Stemmermann GN. The pathology of breast cancer in Japanese women compared to other ethnic groups: a review. Breast Cancer Res Treat. 1991; 18(Suppl 1):S67–72.
- Simpson JS, Briggs K, George R. Breast cancer amongst Filipino migrants: a review of the literature and ten-year institutional analysis. J Immigr Minor Health. 2015;17(3):729–36.
- Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the "National Survey of NHS patients: Cancer". Br J Cancer. 2005;92(11):1971–5.
- Gwyn K, Bondy ML, Cohen DS, Lund MJ, Liff JM, Flagg EW, et al. Racial differences in diagnosis, treatment, and clinical delays in a populationbased study of patients with newly diagnosed breast carcinoma. Cancer. 2004; 100(8):1595–604.
- Ramirez AG, Pérez-Stable EJ, Talavera GA, Penedo FJ, Carrillo JE, Fernandez ME, et al. Time to definitive diagnosis of breast cancer in Latina and non-Hispanic white women: the six cities study. Springerplus. 2013;2(1):84.
- Webber C, Jiang L, Grunfeld E, Groome PA. Identifying predictors of delayed diagnoses in symptomatic breast cancer: a scoping review. Eur J Cancer Care (Engl). 2017;26(2). https://doi.org/10.1111/ecc.12483.

- Brett J, Austoker J, Ong G. Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-Centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. J Public Health Med. 1998;20(4):396–403.
- Poole K, Lyne PA. The 'cues' to diagnosis: describing the monitoring activities of women undergoing diagnostic investigations for breast disease. J Adv Nurs. 2000;31(4):752–8.
- Thorne SE, Harris SR, Hislop TG, Vestrup JA. The experience of waiting for diagnosis after an abnormal mammogram. Breast J. 1999;5(1):42–51.
- The Interprovincial Mobility of Immigrants in Canada: Immigration, Refugee and Citizenship Canada; 2010. Available from: https://www.canada.ca/en/ immigration-refugees-citizenship/corporate/reports-statistics/research/ interprovincial-mobility-immigrants-canada/section-2.html [26 Jul 2018]
- 54. Screening IUPoBC. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–86.
- Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17:63.
- Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and harms of breast Cancer screening: a systematic review. JAMA. 2015;314(15):1615–34.
- Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year followup for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

